First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Triple Negative Breast Cancer
Related studies linked through entity extraction aliases.
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment
- Status
- TERMINATED
- Phase
- PHASE2
Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
- Status
- TERMINATED
- Phase
- PHASE2
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
- Status
- COMPLETED
- Phase
- PHASE1
PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients
- Status
- UNKNOWN
- Phase
- PHASE1
Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1